Autoimmunity in myocardial infarction

International Journal of Cardiology

Volumn 112, Issue 1, 2006, Pages 21-26

  Liao, Yu Hua ^a   Cheng, Xiang ^a  

^a Union Hospital   (China)

Author keywords

Immune therapy; Myocardial infarction; Ventricular remodeling

Indexed keywords

AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOKINE ANTIBODY; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; MYOSIN HEAVY CHAIN; SIMVASTATIN;

ADOPTIVE TRANSFER; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL DIFFERENTIATION; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DISEASE CLASSIFICATION; EXTRACELLULAR MATRIX; HEART INFARCTION; HEART MITOCHONDRION; HEART MUSCLE CELL; HEART VENTRICLE REMODELING; HUMAN; HUMORAL IMMUNITY; INFLAMMATORY INFILTRATE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANIMALS; AUTOANTIGENS; AUTOIMMUNITY; CELL DIFFERENTIATION; CELL PROLIFERATION; HEART FAILURE; HEART FAILURE, CONGESTIVE; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; INFLAMMATION MEDIATORS; MYOCARDIAL INFARCTION; T-LYMPHOCYTES; VENTRICULAR REMODELING;

EID: 33747591898     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2006.05.009     Document Type: Article

References (61)

1. Pfeffer M.A., and Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observation and clinical implications. Circulation 81 (1990) 1161-1172
2. Cowie M.R., Wood D.A., Coats J.S., et al. Incidence and aetiology of heart failure, a population-based study. Eur Heart J 20 (1999) 421-428
3. Blankesteijn W.M., Creemers E., Lutgens E., Cleutjens J.P., Daemen M.J., and Smits J.F. Dynamic of cardiac wound healing following myocardial infarction: observations in genetically altered mice. Acta Physiol Scand 173 (2001) 75-82
4. Entman M.L., Youker K.A., Frangogiannis N., et al. Is inflammation good for the ischemic heart-perspectives beyond the ordinary. Z Kardiol 89 Suppl 9:IX (2000) 82-87
5. Varda-Bloom N., Leor J., Ohad D.G., et al. Cytotoxic T lymphocytes are activated following myocardial infarction and can recognize and kill normal myocytes in vitro. J Mol Cell Cardiol 32 (2000) 2141-2149
6. Liao Y.H., Tao R., Cheng X., et al. Significance of inflammatory response in myocardium after acute myocardial infarction. Mol Cardiol Chin 2 3 (2002) 7-9
7. Herskowitz A., Choi S., Ansari A.A., and Wesselingh S. Cytokine mRNA expression in postischemic/reperfused myocardium. Am J Pathol 146 2 (1995) 419-428
8. Ono K., Matsumori A., Shioi T., Furukawa Y., and Sasayama S. Cytokine gene expression after myocardial infarction in rat hearts: possible implication in left ventricular remodeling. Circulation 98 2 (1998) 149-156
9. Irwin M.W., Mak S., Mann D.L., et al. Tissue expression and immunolocalization of tumor necrosis factor-alpha in postinfarction dysfunctional myocardium. Circulation 99 11 (1999) 1492-1498
10. Zhang J., Cheng X., Liao Y.H., et al. Simvastatin regulates myocardial cytokine expression and improves ventricular remodeling in rats after acute myocardial infarction. Cardiovasc Drugs Ther 19 1 (2005) 13-21
11. Cheng X., Liao Y.H., Li B., et al. Changes of rat lymphocyte proliferation and cytotoxic activity after acute myocardial infarction in vitro. Chin J Pathophysiol 21 9 (2005) 1848-1850
12. Maisel A., Cesario D., Baird S., Rehman J., Haghighi P., and Carter S. Experimental autoimmune myocarditis produced by adoptive transfer of splenocytes after myocardial infarction. Circ Res 82 (1998) 458-463
13. Tao R., Liao Y.H., Cheng X., et al. Adoptive transfer of splenocytes of acute myocardial infarction rats mediated myocardial injury. Chin J Immunol 19 (2003) 642-644
14. Rose N.R., Beisel K.W., Herskowitz A., et al. Cardiac myosin and autoimmune myocarditis. Ciba Found Symp 129 (1987) 3-24
15. Wang Z.H., Liao Y.H., Dong J.H., et al. Experimental study of cardiac myosin-induced autoimmune cardiomyopathy. Chin J Cardiol 31 12 (2003) 937-940
16. Wang Z.H., Liao Y.H., Tu Y.S., et al. Myosin-induced autoimmune myocarditis in Balb/c mice. J TongJi Med Univ 19 2 (1999) 112-114
17. De Scheerder I., Vandekerckhove J., Robbrecht J., et al. Post-cardiac injury syndrome and an increased humoral immune response against the major contractile proteins (actin and myosin). Am J Cardiol 56 10 (1985) 631-633
18. De Scheerder I.K., De Buyzere M.L., Delanghe J.R., Clement D.L., and Wieme R.J. Anti-myosin humoral immune response following cardiac injury. Autoimmunity 4 1-2 (1989) 51-58
19. Wang Z.H., Tu Y.S., Liao Y.H., et al. Preliminary study of antibody against myosin in dilated cardiomyopathy. J Clin Cardiol 21 (1996) 1-3 [Suppl]
20. Zhang J., Chen J., Liao Y.H., et al. Myocardial inflammation and remodeling driven by cardiac myosin specific-T lymphocytes. J Hong Kong Coll Cardiol 13 2 (2005) 130
21. Zhang J., Yu Z.X., Fujita S., Yamaguchi M.L., and Ferrans V.J. Interstitial dendritic cells of the rat heart. Quantitative and ultrastructural changes in experimental myocardial infarction. Circulation 87 3 (1993) 909-920
22. Cheng X., Liao Y.H., Ge H.X., et al. Th1/Th2 functional imbalance after acute myocardial infarction: coronary arterial inflammation or myocardial inflammation. J Clin Immunol 25 3 (2005) 246-253
23. Parissis J.T., Adamopoulos S., Venetsanou K.F., Mentzikof D.G., Karas S.M., and Kremastinos D.T. Serum profiles of C-C chemokines in acute myocardial infarction: possible implication in postinfarction left ventricular remodeling. J Interferon Cytokine Res 22 2 (2002) 223-229
24. Kaikita K., Hayasaki T., Okuma T., Kuziel W.A., Ogawa H., and Takeya M. Targeted deletion of CC chemokine receptor 2 attenuates left ventricular remodeling after experimental myocardial infarction. Am J Pathol 165 2 (2004) 439-447
25. Hayashidani S., Tsutsui H., Shiomi T., et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 108 17 (2003) 2134-2140
26. Ge H.X., Liao Y.H., Cheng X., et al. Alteration of CC chemokines mRNA expression in cardiac tissue after acute myocardial infarction in rats. J Zhengzhou Univ (Med Sci) 40 2 (2005) 186-189
27. Cheng X., Liao Y.H., Ge H.X., et al. The relationship between chemokines expression and heart function in rats after acute myocardial infarction. J Hong Kong Coll Cardiol 13 2 (2005) 98
28. Siveke J.T., and Hamann A. T helper 1 and T helper 2 cells respond differentially to chemokines. J Immunol 160 (1998) 550-554
29. Pang H., Liao Y.H., Tu Y.S., et al. Effect of anti-cardiac myosin antibody on prognosis of patients with acute myocardial infarction. J Tongji Med Univ 20 (2000) 46-48
30. Melguizo C., Prados J., Velez C., Aranega A.E., Marchal J.A., and Aranega A. Clinical significance of antiheart antibodies after myocardial infarction. Jpn Heart J 38 (1997) 779-786
31. Moraru M., Roth A., Keren G., and George J. Cellular autoimmunity to cardiac myosin in patients with a recent myocardial infarction. Int J Cardiol 107 1 (2006) 61-66
32. Gheno G., Libardoni M., Zeppellini R., and Cucchini F. C-reactive protein on admission as a predictor of in-hospital death in the elderly with acute myocardial infarction. Cardiologia 44 12 (1999) 1023-1028
33. Berton G., Cordiano R., Palmieri R., Pianca S., Pagliara V., and Palatini P. C-reactive protein in acute myocardial infarction: association with heart failure. Am Heart J 145 6 (2003) 1094-1101
34. Latini R., Maggioni A.P., Peri G., et al. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 110 16 (2004) 2349-2354
35. Fahim M.R., Halim S.M., and Kamel I. Tumor necrosis factor alpha in patients with acute myocardial infarction. Egypt J Immunol 11 1 (2004) 31-37
36. Roberts R., DeMello V., and Sobel B.E. Deleterious effects of methylprednisolone in patients with myocardial infarction. Circulation (1976) 204-206
37. Kloner R.A., Fishbein M.C., Lew H., Maroko P.R., and Braunwald E. Mummification of the infarcted myocardium by high dose corticosteroids. Circulation 1 (1978) 56-63
38. Mann D.L., McMurray J.J., Packer M., et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109 (2004) 1594-1602
39. Chung E.S., Packer M., Lo K.H., et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation 107 (2003) 3133-3140
40. Cheng X., Liao Y.H., Li B., et al. Effects of early treatment with metoprolol on myocardial inflammatory cytokine expression and heart function in rats with acute myocardial infarction. Chin J Cardiol 33 (2005) 448-452
41. Lapointe N., Blais Jr. C., Adam A., et al. Comparison of the effects of an angiotensin-converting enzyme inhibitor and a vasopeptidase inhibitor after myocardial infarction in the rat. J Am Coll Cardiol 39 (2002) 1692-1698
42. Bauersachs J., Galuppo P., Fraccarollo D., Christ M., and Ertl G. Improvement of left ventricular remodeling and function by Hydroxymethylglutary coenzyme A reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 104 (2001) 982-985
43. Tiefenbacher C.P., Kapitza J., Dietz V., Lee C.H., and Niroomand F. Reduction of myocardial infarct size by fluvastatin. Am J Physiol Heart Circ Physiol 285 (2003) H59-H64
44. Lee T.M., Chou T.F., and Tsai C.H. Effects of pravastatin on cardiomyocyte hypertrophy and ventricular vulnerability in normolipicemic rats after myocardial infarction. J Moll Cell Cardiol 35 (2003) 1449-1459
45. Node K., Fujita M., Kitakaze M., Hori M., and Liao J.K. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 108 (2003) 839-843
46. Rezaie-Majd A., Maca T., Bucek R.A., et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 22 (2002) 1194-1199
47. Inoue I., Goto S., Mizotani K., et al. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of mRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells. Life Sci 67 (2000) 863-876
48. Cheng X., Liao Y.H., Zhang J.Y., et al. Effects of atorvastatin on Th polarization in patients with acute myocardial infarction. Eur J Heart Fail 7 7 (2005) 1099-1104
49. Groenning B.A., Nilsson J.C., Sondergaard L., Fritz-Hansen T., Larsson H.B., and Hildebrandt P.R. Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. J Am Coll Cardiol 36 (2000) 2072-2080
50. Packer M., Colucci W.S., Sackner-Bernstein J.D., et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation 94 (1996) 2793-2799
51. Waagstein F., Stromblad O., Andersson B., et al. Increased exercise ejection fraction and reversed remodeling after long-term treatment with metoprolol in congestive heart failure: a randomized, stratified, double-blind, placebo-controlled trial in mild to moderate heart failure due to ischemic or idiopathic dilated cardiomyopathy. Eur J Heart Fail 5 (2003) 679-691
52. Murray D.R., Prabhu S.D., and Chandrasekar B. Chronic beta-adrenergic stimulation induces myocardial proinflammatory cytokine expression. Circulation 101 (2000) 2338-2341
53. Li B., Liao Y.H., Cheng X., et al. The effect of carvedilol on tumor necrosis factor-α and matrix metalloproteinase in rats after acute myocardial infarction. Chin Hosp Pharm J 24 11 (2004) 659-661
54. Li B., Liao Y.H., Cheng X., et al. Effects of carvedilol on the expression of IL-1beta and collagen precipitation in myocardium in post-myocardial infarction rats. Nat Med J Chin 16;85 6 (2005) 416-418
55. Prabhu S.D., Chandrasekar B., Murray D.R., and Freeman G.L. Beta-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. Circulation 101 (2000) 2103-2109
56. Mayer B., Holmer S.R., Hengstenberg C., Lieb W., Pfeifer M., and Schunkert H. Functional improvement in heart failure patients treated with beta-blockers is associated with a decline of cytokine levels. Int J Cardiol 103 2 (2005) 182-186
57. Tatli E., and Kurum T. A controlled study of the effects of carvedilol on clinical events, left ventricular function and proinflammatory cytokines levels in patients with dilated cardiomyopathy. Can J Cardiol 21 4 (2005) 344-348
58. Cinquegrana G., D'Aniello L., Landi M., et al. Effects of different degrees of sympathetic antagonism on cytokine network in patients with ischemic dilated cardiomyopathy. J Card Fail 11 3 (2005) 213-219
59. Ohtsuka T., Hamada M., Hiasa G., et al. Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. J Am Coll Cardiol 37 2 (2001) 412-417
60. Gullestad L., Aukrust P., Ueland T., et al. Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol 34 7 (1999) 2061-2067
61. Mohler E.R., Soremsen L.C., Ghali J.K., et al. Role of cytokines in the mechanism of action of amlodipine: the PRAISE heart failure trial. Prospective randomized amlodipine survival evaluation. J Am Coll Cardiol 30 (1997) 35-41